ANVSAnnovis Bio, Inc.

NYSE annovisbio.com


$ 11.04 $ 3.02 (37.38 %)    

Friday, 05-Jul-2024 15:59:59 EDT
QQQ $ 495.80 $ 5.12 (1.04 %)
DIA $ 393.71 $ 0.87 (0.22 %)
SPY $ 554.29 $ 3.18 (0.58 %)
TLT $ 92.56 $ 0.76 (0.83 %)
GLD $ 220.89 $ 2.94 (1.35 %)
$ 11.1
$ 8.03
$ 0.00 x 0
$ 0.00 x 0
$ 8.00 - $ 11.41
$ 4.53 - $ 22.49
16,203,599
na
120.15M
$ 1.62
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-10-2024 03-31-2024 10-Q
2 03-29-2024 12-31-2023 10-K
3 11-08-2023 09-30-2023 10-Q
4 08-14-2023 06-30-2023 10-Q
5 05-10-2023 03-31-2023 10-Q
6 03-31-2023 12-31-2022 10-K
7 11-08-2022 09-30-2022 10-Q
8 08-08-2022 06-30-2022 10-Q
9 05-04-2022 03-31-2022 10-Q
10 03-02-2022 12-31-2021 10-K
11 11-03-2021 09-30-2021 10-Q
12 07-28-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 03-03-2021 12-31-2020 10-K
15 11-04-2020 09-30-2020 10-Q
16 07-29-2020 06-30-2020 10-Q
17 05-05-2020 03-31-2020 10-Q
18 03-25-2020 12-31-2019 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 why-nio-shares-are-trading-lower-by-over-8-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of NIO Inc. (NYSE:NIO) fell sharply during Friday's session after the company disclosed that Steven Wei Feng has res...

 whats-going-on-with-annovis-shares-today

Annovis Bio shares rise in premarket trading on positive Phase III Parkinson's study results for buntanetap, showing cognit...

 tesla-paramount-global-annovis-bio-eli-lilly-amazon-why-these-5-stocks-are-on-investors-radars-today

On Tuesday, the Dow Jones Industrial Average rose by 0.4%, closing at $39,331.85, while the S&P 500 also ended the day in p...

 rodman--renshaw-reiterates-buy-on-annovis-bio-maintains-67-price-target

Rodman & Renshaw analyst Elemer Piros reiterates Annovis Bio (NYSE:ANVS) with a Buy and maintains $67 price target.

 whats-going-with-annovis-bio-shares-tuesday

Annovis announced new data from its Phase III Parkinson's study. The study showed improvements on the Unified Parkinson'...

 annovis-bio-files-provisional-patent-for-new-manufacturing-process-of-crystalline-form-of-buntanetap-which-has-demonstrated-exceptional-stability-and-efficacy

This patent encompasses the methods for manufacturing the new crystalline form of buntanetap (CAS# 3032752-92-1), which has dem...

 hc-wainwright--co-reiterates-buy-on-annovis-bio-maintains-23-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Annovis Bio (NYSE:ANVS) with a Buy and maintains $23 price tar...

 annovis-bios-recent-phase-iiiii-alzheimers-study-of-buntanetap-showed-statistically-significant-efficacy-and-safety-in-both-carriers-and-non-carriers-of-apolipoprotein-e4-a-genetic-cause-of-ad

Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage drug platform company developing novel ...

 rodman--renshaw-initiates-coverage-on-annovis-bio-with-buy-rating-announces-price-target-of-67

Rodman & Renshaw initiates coverage on Annovis Bio (NYSE:ANVS) with a Buy rating and announces Price Target of $67.

 hc-wainwright--co-maintains-buy-on-annovis-bio-lowers-price-target-to-23

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Annovis Bio (NYSE:ANVS) with a Buy and lowers the price target ...